Show simple item record

Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience

dc.contributor.authorErgezen, Bilgesu
dc.contributor.authorSelvi, Oguzhan
dc.contributor.authorEgeli, Bugra Han
dc.contributor.authorUĞURLU, Serdal
dc.contributor.authorOzdogan, Huri
dc.date.accessioned2021-12-10T10:08:31Z
dc.date.available2021-12-10T10:08:31Z
dc.date.issued2021
dc.identifier.citationUĞURLU S., Ergezen B., Egeli B. H. , Selvi O., Ozdogan H., "Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience", RHEUMATOLOGY, cilt.60, sa.5, ss.2327-2332, 2021
dc.identifier.issn1462-0324
dc.identifier.othervv_1032021
dc.identifier.otherav_2b595289-c08f-4e4d-bf07-4f9391d1bd23
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169275
dc.identifier.urihttps://doi.org/10.1093/rheumatology/keaa596
dc.description.abstractObjectives. Anakinra is proven to be effective in controlled trials in terms of attack frequency and subclinical inflammation in colchicine-resistant patients. The objective of this study was to review the patients followed in our single centre with FMF who received anakinra because of insufficient colchicine response.
dc.language.isoeng
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectRheumatology
dc.subjectHealth Sciences
dc.titleAnakinra treatment in patients with familial Mediterranean fever: a single-centre experience
dc.typeMakale
dc.relation.journalRHEUMATOLOGY
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume60
dc.identifier.issue5
dc.identifier.startpage2327
dc.identifier.endpage2332
dc.contributor.firstauthorID2645835


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record